Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of today’s top gainers. The company’s shares are currently up 6.58% on the day to $800.71.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion.
So far today, approximately 1.15M shares of Regeneron Pharmaceuticals, Inc. have been exchanged, as compared to an average 30-day volume of 526.28k shares.
Regeneron Pharmaceuticals, Inc. share prices have moved between a 52-week high of $812.69 and a 52-week low of $538.01. The stock has moved 0.49% over the past week.
Mentions of Regeneron Pharmaceuticals, Inc. on Twitter have totaled 192 in the past 24 hours, as compared to 53 in the prior 24 hours (a change of 262.26%). On Stocktwits, posts totaled 40 for the same period, as compared to 11 in the prior 24 hours (a change of 263.64%).
To learn more about Regeneron Pharmaceuticals, Inc., visit the company’s website at https://www.regeneron.com.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
